Paul Ricci Net Worth

The estimated Net Worth of Paul Ricci is at least $63 Million dollars as of 24 June 2019. Mr. Ricci owns over 40,000 units of Personalis Inc stock worth over $119,000 and over the last 19 years he sold PSNL stock worth over $61,835,736. In addition, he makes $1,004,360 as Independent Director at Personalis Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Ricci PSNL stock SEC Form 4 insiders trading

Paul has made over 37 trades of the Personalis Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 40,000 units of PSNL stock worth $680,000 on 24 June 2019.

The largest trade he's ever made was exercising 1,000,000 units of Personalis Inc stock on 6 June 2017 worth over $16,440,000. On average, Paul trades about 64,488 units every 22 days since 2005. As of 24 June 2019 he still owns at least 20,000 units of Personalis Inc stock.

You can see the complete history of Mr. Ricci stock trades at the bottom of the page.

Paul Ricci biography

Paul A. Ricci serves as Independent Director of the Company. He has served as an Advisor to Lightspeed Venture Partners, an early-stage technology venture capital firm. Since September 2018, Mr. Ricci has served as an Advisor to Warburg Pincus, a private equity firm. Mr. Ricci served as Chief Executive Officer of Nuance Communications, Inc., a computer software technology company, from August 2000 to March 2018 and as its Chairman from March 1999 to February 2018. Mr. Ricci holds a B.A. and an M.A. in Economics from Stanford University. Mr. Ricci was selected to serve on our board of directors because of his management abilities and experience.

What is the salary of Paul Ricci?

As the Independent Director of Personalis Inc, the total compensation of Paul Ricci at Personalis Inc is $1,004,360. There are 3 executives at Personalis Inc getting paid more, with Aaron Tachibana having the highest compensation of $3,003,510.

How old is Paul Ricci?

Paul Ricci is 63, he's been the Independent Director of Personalis Inc since 2019. There are 5 older and 9 younger executives at Personalis Inc. The oldest executive at Personalis Inc is A. Blaine Bowman, 73, who is the Independent Director.

What's Paul Ricci's mailing address?

Paul's mailing address filed with the SEC is C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK, CA, 94025.

Insiders trading at Personalis Inc

Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci, and Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.

What does Personalis Inc do?

personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.

Complete history of Mr. Ricci stock trades at Nuance Communications Inc and Personalis Inc

Personalis Inc executives and stock owners

Personalis Inc executives and other stock owners filed with the SEC include:

• Aaron Tachibana,
  Chief Financial Officer
• Clinton Musil,
  Chief Business Officer
• John Stephen West,
  Co-Founder, CEO, Pres & Director
• Paul Ricci,
  Independent Director
• John West,
  President, Chief Executive Officer, Director
• Dr. Richard Chen M.D., M.S., MS,
  Sr. VP of R&D and Chief Medical Officer
• Richard Chen,
  Chief Science Officer
• Aaron L. Tachibana,
  Sr. VP & CFO
• Dr. Richard Chen M.S., M.D., MS,
  Chief Scientific Officer
• A. Blaine Bowman,
  Independent Director
• Alan Colowick,
  Independent Director
• Karin Eastham,
  Independent Director
• Jonathan MacQuitty,
  Independent Chairman of the Board
• Kenneth Ludlum,
  Independent Director
• Patrick Balthrop,
  Independent Director
• Stephen Moore,
  General Counsel
• Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Prof. Russ B. Altman M.D., Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Michael J. Fitzpatrick,
  VP of Worldwide Sales
• Stephen M. Moore J.D.,
  VP, Gen. Counsel & Corp. Sec.
• Carol J. Tillis,
  VP of Fin. & Admin.
• Dr. Michael Snyder Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Dr. Atul Butte,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Dr. Euan A. Ashley M.D., Ph.D., FRCP, DPHIL,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Prof. Russ B. Altman,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Kenneth J Widder,
  
• Olivia Kyusuk Bloom,
  
• Ken Ludlum,
  Director
• Mdv Partners, L.L.C.Mdv Ix ...,
  
• Venture Partners Viii Lp Li...,
  
• Venture Partners Select Iv,...,
  
• Llp Abingworth,
  
• Christopher M Hall,
  PRESIDENT AND CEO
• Venture Partners Select Iv,...,
  
• Ai, Inc. Tempus,
  10% owner
• Lonnie Shoff,